Penetration of intact blood-brain barrier by doripenem

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3637-3638

  Margetis, K ^a   Dimaraki, E ^a   Charkoftaki, G ^a   Vryonis, E ^b   Markantonis, S ^a   Boutos, N ^a   Archontaki, H ^a   Sakas, D E ^a   Valsami, G ^a   Skoutelis, A ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DORIPENEM; VANCOMYCIN;

ANTIBIOTIC THERAPY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INDWELLING CATHETER; INFECTION PREVENTION; LETTER; MENINGITIS; PREOPERATIVE CARE; PRIORITY JOURNAL; SPASTICITY;

ANTI-BACTERIAL AGENTS; BLOOD-BRAIN BARRIER; CARBAPENEMS; HUMANS; INJECTIONS, SPINAL;

EID: 79959210315     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01634-10     Document Type: Letter

References (12)

1. Castanheira, M., R. N. Jones, and D. M. Livermore. 2009. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis. 63:426-433.
2. Fritsche, T. R., M. G. Stilwell, and R. N. Jones. 2005. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11:974-984.
3. Horiuchi, M., et al. 2006 Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 222:114-124. (Pubitemid 44275125)
4. Ikeda, K., et al. 2008. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867:20-25.
5. Jones, R. N., H. K. Huynh, D. J. Biedenbach, T. R. Fritsche, and H. S. Sader. 2004. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54:144-154.
6. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
7. Kim, A., M. A. Banevicius, and D. P. Nicolau. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502.
8. Kobayashi, Y. 2005. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother. 11:259-261.
9. Matthews, S. J., and J. W. Lancaster. 2009. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin. Ther. 31:42-63.
10. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48:1313-1319.
11. Rodríguez-Baño, J., et al. 2008. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin. Microbiol. Infect. 14:276-278.
12. Sacar, S., et al. 2006. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect. Dis. 6:43.